Pfizer Inc. (PFE) — Analysis Summary
Pfizer Inc. (PFE) has a market cap of $137.76B with year-over-year revenue growth of -1.6%. Net margin stands at 12.4%. The stock trades at a P/E ratio of 18.4.
Key Takeaways
- Revenue changed -1.6% year-over-year
- Net margin of 12.4%
- P/E ratio of 18.4
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, PFE posted revenue growth of -1.6% and trades at a P/E of 18.4.
Pfizer Inc. (PFE)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.0x — earnings do not cover interest payments
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
75,000
Headquarters
NEW YORK, NY
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.72
Dividend Yield
7.12%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.